We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > castration-resistant

News List

Janssen announces European Commission approval of ERLEADA (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease firstwordpharma
January 17, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted marketing authorisation for ERLEADA® (apalutamide), a next generation oral androgen receptor inhibitor for the treatment of adult patie
Sun Pharma drug combo scoresFDA approval in advanced castration-resistant prostate cancer pharmafile
May 25, 2018
Sun Pharma is celebrating with the announcement that its CYP17 inhibitor Yonsa (abiraterone acetate) has been awarded FDA approval in combination with methylprednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult